{"entity":{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","aka":[],"tldr":"Adding the blood-vessel blocker bevacizumab to first-line chemotherapy delayed relapse by a few months but did not extend life overall.","summary":"GOG-0218 (1,873 patients): PFS 14.1 vs 10.3 months with concurrent-plus-maintenance bevacizumab (HR 0.72); no OS benefit (NEJM 2011). ICON7 (1,528): modest PFS gain, with an OS benefit confined to high-risk (stage IV or suboptimally debulked) disease. Bevacizumab became a first-line option, mainly for high-risk patients and as the partner for olaparib in PAOLA-1.","status":"mixed","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT00262847","url":"https://clinicaltrials.gov/study/NCT00262847"},{"label":"GOG-0218, NEJM 2011","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1104390"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":["vegf"],"drugs":["bevacizumab","carboplatin","paclitaxel"],"companies":["mrc-ctu","arcagy-gineco","gog-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jonathan-ledermann"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00262847","phase":"3","setting":"Newly diagnosed advanced ovarian cancer: carboplatin-paclitaxel ± bevacizumab with bevacizumab maintenance","sponsor":"GOG; MRC/ICON","result":"GOG-0218 PFS 14.1 vs 10.3 months (HR 0.72); no OS benefit.","started":"2005-09","yearReported":2011,"enrolled":3401,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (GOG-0218)","primary":true,"unit":"months","arms":[{"name":"Bevacizumab throughout","value":14.1},{"name":"Chemotherapy alone","value":10.3}],"hr":0.72,"ci":[0.63,0.82],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1104390"}]},"route":"/trials/gog-0218-icon7/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"},{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/"}],"person":[{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/"}]}}